Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;68(10):348-358.
doi: 10.1111/1348-0421.13171. Epub 2024 Sep 6.

Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin

Takuhiro Matsumura  1 , Mayu Kitamura  1 , Sho Amatsu  1 , Aki Yamaguchi  1 , Nobuhide Kobayashi  1 , Masahiro Yutani  1   2 , Yukako Fujinaga  1
Affiliations

Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin

Takuhiro Matsumura et al. Microbiol Immunol. 2024 Oct.

Abstract

Botulism is a deadly neuroparalytic condition caused by the botulinum neurotoxin (BoNT) produced by Clostridium botulinum and related species. Toxin-neutralizing antibodies are the most effective treatments for BoNT intoxication. We generated human monoclonal antibodies neutralizing type B botulinum neurotoxin (BoNT/B), designated M2 and M4. The combination of these antibodies exhibited a strong neutralizing effect against BoNT/B toxicity. In this study, we analyzed the mechanisms of action of these antibodies in vitro. M4 binds to the C-terminus of the heavy chain (the receptor-binding domain) and inhibits BoNT/B binding to neuronal PC12 cells. Although M2 recognized the light (L) chain (the metalloprotease domain), it did not inhibit substrate (VAMP2) cleavage in the cleavage assay. M2 increased the surface localization of BoNT/B in PC12 cells at a later time point, suggesting that M2 inhibits the translocation of the L chain from synaptic vesicles to the cytosol. These results indicate that M2 and M4 inhibit the different processes of BoNT/B individually and that multistep inhibition is important for the synergistic effect of the combination of monoclonal antibodies. Our findings may facilitate the development of effective therapeutic antibodies against BoNTs.

Keywords: Clostridium botulinum; botulism; human monoclonal antibody; neurotoxin; therapeutics.

PubMed Disclaimer

References

REFERENCES

    1. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717–766.
    1. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–549.
    1. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis. 2014;209:183–191.
    1. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis. 2014;209:192–202.
    1. Maslanka SE, Lúquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, et al. A novel Botulinum neurotoxin, previously reported as serotype H, has a hybrid‐like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin. J Infect Dis. 2016;213:379–385.

MeSH terms

LinkOut - more resources